A list of the latest medical information from Seagull Pharmacy

Current Location：Home>Medical Information

Checkpoint Inhibitors and Bispecifics Build Momentum Throughout Lymphoma
2022-03-01 16:41:06
Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there...
EU Panel Confirms Recommendation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
2022-03-01 16:35:34
The European Medicines Agency ’ s Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to...
INTELLIA AND REGENERON ANNOUNCE UPDATED PHASE 1 DATA DEMONSTRATING A SINGLE DOSE OF NTLA-2001, INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS, RESULTED IN RAPID, DEEP AND SUSTAINED REDUCTION IN DISEASE-CAUSING PROTEIN
2022-03-01 16:22:27
Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive interim data from an...
NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS
2022-03-01 16:13:59
THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the piv...
FDA Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma
2022-03-01 15:47:42
The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma. The...
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
2022-02-28 17:48:44
KENILWORTH, N.J. TOKYO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that...
LATE-BREAKING PHASE 3 DATA AT 2022 AAAAI ANNUAL MEETING SHOW DUPIXENT® (DUPILUMAB) SIGNIFICANTLY REDUCED ITCH AND HIVES IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
2022-02-28 17:35:00
In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared ...
Axitinib/Pembrolizumab Shows Real-World Efficacy in Frontline Advanced RCC
2022-02-28 17:32:38
A real-world analysis showed that patients with advanced renal cell carcinoma in the United States who received the combination of axitinib and p...
LATE-BREAKING DATA AT 2022 AAAAI ANNUAL MEETING SHOW DUPIXENT® (DUPILUMAB) SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS
2022-02-28 17:13:11
Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) andSanofitoday announced positive detailed results from a second Phase 3 trial that showed Dupixent...
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
2022-02-28 17:02:47
(OXFORDSHIRE, England CONSHOHOCKEN, Penn. ROCKVILLE, Md., US, 25 February 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Co...

<<
<
5
6
7
>
>>
Jump to Page